XML 74 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Agreements - Lilly (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2018
item
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2011
USD ($)
item
Collaborative Agreements disclosures                                      
Revenue from contract with customer   $ 44,864,000 $ 13,281,000 $ 15,542,000 $ 8,584,000 $ 13,416,000 $ 10,928,000 $ 9,287,000 $ 19,815,000 $ 39,448,000 $ 8,480,000 $ 39,020,000 $ 28,499,000 $ 82,271,000 $ 53,446,000 $ 115,447,000      
Remaining arrangement consideration to be recognized as license revenue   127,123,000       80,485,000               127,123,000 80,485,000        
Expense related to excess inventory   26,055,000 21,015,000 28,559,000 38,893,000 43,681,000 47,243,000 38,701,000 44,831,000 39,843,000 31,689,000 35,319,000 32,888,000 114,522,000 174,456,000 139,739,000      
Lilly                                      
Collaborative Agreements disclosures                                      
Number of development and commercialization licenses | item                                     3
Number of licenses terminated | item 3                                    
Upfront payment | Lilly                                      
Collaborative Agreements disclosures                                      
Revenue from contract with customer                                     $ 20,000,000
License and milestone fees                                      
Collaborative Agreements disclosures                                      
Revenue from contract with customer   $ 29,551,000 $ 79,000 5,079,000 79,000 1,747,000 672,000 1,321,000 11,540,000 29,580,000 79,000 31,080,000 18,730,000 34,788,000 15,280,000 79,469,000      
License and milestone fees | Lilly                                      
Collaborative Agreements disclosures                                      
Revenue from contract with customer                             692,000        
Exercise fee | Lilly                                      
Collaborative Agreements disclosures                                      
Revenue from contract with customer                                 $ 2,000,000 $ 2,000,000 $ 2,000,000
Research and development support                                      
Collaborative Agreements disclosures                                      
Revenue from contract with customer       $ 51,000 $ 17,000 218,000 388,000 388,000 383,000 452,000 650,000 902,000 1,478,000 $ 68,000 1,377,000 3,482,000      
Clinical materials revenue                                      
Collaborative Agreements disclosures                                      
Revenue from contract with customer           $ 2,170,000 $ 1,427,000 $ 336,000 $ 702,000 $ 1,829,000 $ 1,248,000 $ 599,000 $ 678,000   $ 4,635,000 $ 4,354,000